UPB Upstream Bio Inc.

Price (delayed)

$7.45

Market cap

$405.43M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.9

Enterprise value

$309.62M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 25

We are a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. We are developing verekitug, the only known antagonist currently in clinical ...

Highlights
The revenue is up by 45% year-on-year and by 16% since the previous quarter
The company's gross profit rose by 45% YoY and by 16% QoQ
The EPS has shrunk by 107% YoY and by 9% QoQ
UPB's net income has dropped by 98% year-on-year and by 9% since the previous quarter

Key stats

What are the main financial stats of UPB

UPB stock price

How has the Upstream Bio stock price performed over time
Intraday
-2.36%
1 week
-10.46%
1 month
-19.98%
1 year
-31.4%
YTD
-72.56%
QTD
-17.22%

Financial performance

How have Upstream Bio's revenue and profit performed over time
Revenue
$3.32M
Gross profit
$3.32M
Operating income
-$171.96M
Net income
-$156.76M
Gross margin
100%
Net margin
-4,719%
UPB's net income has dropped by 98% year-on-year and by 9% since the previous quarter
UPB's operating income has dropped by 81% year-on-year and by 7% since the previous quarter
The revenue is up by 45% year-on-year and by 16% since the previous quarter
The company's gross profit rose by 45% YoY and by 16% QoQ

Price vs fundamentals

How does UPB's price correlate with its fundamentals

Growth

What is Upstream Bio's growth rate over time

Valuation

What is Upstream Bio stock price valuation
P/E
N/A
P/B
1.33
P/S
121.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
93.2
The EPS has shrunk by 107% YoY and by 9% QoQ
The P/B is 45% less than the last 4 quarters average of 2.5
The company's equity fell by 32% YoY and by 11% QoQ
The stock's price to sales (P/S) is 60% less than its last 4 quarters average of 309.7
The revenue is up by 45% year-on-year and by 16% since the previous quarter

Efficiency

How efficient is Upstream Bio business performance
UPB's ROA has dropped by 67% year-on-year and by 19% since the previous quarter
The company's return on invested capital has shrunk by 59% YoY and by 26% QoQ
The ROS fell by 37% YoY but it rose by 6% QoQ
The return on equity has increased by 26% year-on-year but it has declined by 20% since the previous quarter

Dividends

What is UPB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for UPB.

Financial health

How did Upstream Bio financials performed over time
The quick ratio has dropped by 52% year-on-year and by 15% since the previous quarter
UPB's current ratio has dropped by 51% year-on-year and by 12% since the previous quarter
The debt is 100% smaller than the equity
The debt has declined by 34% year-on-year and by 12% since the previous quarter
The company's equity fell by 32% YoY and by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.